Dr Reddy's Labs launches India's first DCGI─approved semaglutide injection 'Obeda' for type 2 diabetes
Dr Reddy's Laboratories Ltd., a global pharmaceutical company, announced the launch of its injectable semaglutide under the brand name Obeda, marking an important step in expanding access to advanced
Pharma Biz
via Pharma Biz
Updated 1h ago
Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Gainey Capital (CVE:GNC) Shares Cross Above 50 Day Moving Average – Here’s What Happened
Next
Michael Jackson’s Estate Fires Back at Paris Jackson After She Slams Biopic
Related Articles
)
Health'Go to Iran': The 3-word ultimatum from General Asim Munir that is tearing Pakistan apart
Zee Media Bureau-3h ago-1 sources
HealthZydus Launches Semaglutide Injection in an Innovative, Reusable Multi-Dose Pen Device in India
admin-4h ago-1 sources
HealthMeningitis update as UKHSA confirms five new cases in horror outbreak
Liam Doyle-12h ago-1 sources